- Home
- NAGE vs CUE Comparison
NAGE vs CUE Comparison
Compare NAGE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | CUE |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.0M | 233.5M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NAGE | CUE |
|---|---|---|
| Price | $3.11 | $27.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $16.00 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 538.1K | 176.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.82 | 61.11 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $129,423,000.00 | $27,466,000.00 |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $35.22 | ★ N/A |
| Revenue Growth | 29.95 | ★ 195.75 |
| 52 Week Low | $2.87 | $0.17 |
| 52 Week High | $10.52 | $45.50 |
Technical Indicators
Market Signals| Indicator | NAGE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 49.74 |
| Support Level | $2.91 | $24.35 |
| Resistance Level | $3.61 | $33.95 |
| Average True Range (ATR) | 0.11 | 3.41 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 43.42 | 43.34 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.